NYSE : EW
Edwards Lifesciences Corporation — Key statistics
Healthcare · Medical Devices · United States
Last price 92.01 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 53.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 53.76B |
| Enterprise Value | 50.18B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 576.40M |
| Shares Outstanding | 576.40M |
| Shares Change (YoY) | -1.64% |
| Shares Change (QoQ) | -0.53% |
| Owned by Insiders (%) | 0.19% |
| Owned by Institutions (%) | 92.73% |
| Float | 574.70M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 54.25 |
| Forward PE | 29.72 |
| PS Ratio | 8.40 |
| Forward PS | 7.74 |
| PB Ratio | 5.00 |
| P/TBV Ratio | 7.51 |
| P/FCF Ratio | 38.14 |
| P/OCF Ratio | 31.79 |
| PEG Ratio | 2.58 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 50.86 |
| EV / Sales | 7.85 |
| EV / EBITDA | 25.59 |
| EV / EBIT | 27.91 |
| EV / FCF | 35.65 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.52 |
| Quick Ratio | 3.45 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.35 |
| Debt / FCF | 0.49 |
| Interest Coverage | 89.77 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 9.18% |
| Return on Assets (ROA) | 8.37% |
| Return on Invested Capital (ROIC) | 17.39% |
| Return on Capital Employed (ROCE) | 14.82% |
| Weighted Average Cost of Capital (WACC) | 8.91% |
| Revenue Per Employee | $407,019 |
| Profits Per Employee | $62,806 |
| Employee Count | 16,000 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.27 |
Taxes
| Measure | Value |
|---|
| Income Tax | 439.00M |
| Effective Tax Rate | 30.97% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.86 |
| 52-Week Price Change | +13.11% |
| 50-Day Moving Average | 88.21 |
| 200-Day Moving Average | 85.47 |
| Relative Strength Index (RSI) | 62.77 |
| Average Volume (20 Days) | 3,995,932 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.33M |
| Short Previous Month | 9.09M |
| Short % of Shares Out | 1.62% |
| Short % of Float | 1.62% |
| Short Ratio (days to cover) | 2.43 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.51B |
| Gross Profit | 5.07B |
| Operating Income | 1.83B |
| Pretax Income | 1.42B |
| Net Income | 1.00B |
| EBITDA | 2.00B |
| EBIT | 1.83B |
| Earnings Per Share (EPS) | $1.72 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.25B |
| Total Debt | 704.40M |
| Net Cash | 3.58B |
| Net Cash Per Share | $6.21 |
| Equity (Book Value) | 10.72B |
| Book Value Per Share | 18.41 |
| Working Capital | 5.31B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 1.72B |
| Capital Expenditures | -286.70M |
| Depreciation & Amortization | 165.50M |
| Net Borrowing | n/a |
| Free Cash Flow | 1.43B |
| FCF Per Share | $2.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | 77.84% |
| Operating Margin | 28.12% |
| Pretax Margin | 21.77% |
| Profit Margin | 15.43% |
| EBITDA Margin | 30.66% |
| EBIT Margin | 28.12% |
| FCF Margin | 22.01% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.64% |
| Shareholder Yield | 1.64% |
| Earnings Yield | 1.84% |
| FCF Yield | 2.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $101.87 |
| Price Target Difference | 9.23% |
| Analyst Consensus | Buy |
| Analyst Count | 30 |
| Revenue Growth Forecast (3Y) | 10.46% |
| EPS Growth Forecast (3Y) | 13.95% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 1, 2020 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 11.92 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |